Risk adjusted net present value: What is the current valuation of Vigil Neuroscience’s Iluzanebart?
Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases.
Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases.
What's Your Reaction?
